摘要
目的：评价比阿培南治疗基础疾病患者中、重度细菌感染疗效性和安全性。方法将44例基础疾病中、重度细菌感染患者随机分为对照组（哌拉西林/他唑巴坦组）24例和治疗组（比阿培南组）20例，对照组哌拉西林/他唑巴坦2.25～4.5 g/次，3次/d静脉滴注，治疗组注射用比阿培南0.3 g/次，3次/d静脉滴注，疗程10 d，观察两组患者的临床疗效和不良反应。结果比阿培南组与哌拉西林/他唑巴坦组临床有效率分别为75%（15/20）和70.8%（17/24），细菌清除率分别为70.0%（14/20）和66.7%（16/24），差异均无统计学意义（P＞0.05）；治疗组患者不良反应发生率为10.0%（2/20）。结论比阿培南治疗基础疾病患者中、重度细菌感染疗效确切且使用安全。
Objective To evaluate the efifcacy and safety of biapenem in the treatment of moderate and severe bacterial infection in patients with underlying diseases. Methods Total of 44 patients with moderate and severe bacterial infection of underlying diseases, were randomly divided into the control group （piperacillin/tazobactam group） with 24 cases and the treatment groups （biapenem group） with 20 cases, control group were treated with piperacillin/tazobactam 2.25-4.5 g for 3 times a day intravenously, 0.3 g biapenem was used for treatment group intravenously 3 times a day, the course of treatment was generally 10 days, the efifcacy and adverse reactions were observed of two groups, respectively. Results The efifcacious rates of biapenem and piperacillin/tazobactam were 75.0% （15/20） and 70.8% （17/24）, respectively. The bacterial clearance rate was 70.0%（14/20） in biapenem treatment group and 66.7%（16/24） in piperacillin/tazobactam treatment group with no significant difference. The clinical efficacy of biapenem was 75.0%treatment, while the adverse reaction rate was 10.0%. Conclusion Biapenem is effective and safe for treatment of moderate and severe bacterial infection in patients with underlying diseases.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2014年第1期48-51,共4页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
关键词
比阿培南
基础疾病
中重度细菌感染
有效性
安全性
Biapenem
Underlying diseases
Moderate and severe bacterial infection
Effect
Safety
